{
  "actions": [
    {
      "acted_at": "2008-07-31", 
      "committee": "Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned", 
      "references": [], 
      "status": "REFERRED", 
      "text": "Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.", 
      "type": "referral"
    }, 
    {
      "acted_at": "2008-07-31", 
      "committee": "House Energy and Commerce", 
      "references": [], 
      "text": "Referred to House Energy and Commerce", 
      "type": "referral"
    }, 
    {
      "acted_at": "2008-07-31", 
      "in_committee": "House Energy and Commerce", 
      "references": [], 
      "subcommittee": "Health", 
      "text": "Referred to the Subcommittee on Health.", 
      "type": "referral"
    }, 
    {
      "acted_at": "2008-07-31", 
      "committee": "House Ways and Means", 
      "references": [], 
      "text": "Referred to House Ways and Means", 
      "type": "referral"
    }
  ], 
  "amendments": [], 
  "bill_id": "hr6684-110", 
  "bill_type": "hr", 
  "committees": [
    {
      "activity": [
        "referral", 
        "in committee"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF"
    }, 
    {
      "activity": [
        "referral"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF", 
      "subcommittee": "Subcommittee on Health", 
      "subcommittee_id": "14"
    }, 
    {
      "activity": [
        "referral", 
        "in committee"
      ], 
      "committee": "House Ways and Means", 
      "committee_id": "HSWM"
    }
  ], 
  "congress": "110", 
  "cosponsors": [], 
  "enacted_as": null, 
  "history": {
    "awaiting_signature": false, 
    "enacted": false, 
    "vetoed": false
  }, 
  "introduced_at": "2008-07-31", 
  "number": "6684", 
  "official_title": "To amend part D of title XVIII of the Social Security Act to apply the exceptions process for tiered formulary drugs to specialty tier drugs and to limit to 25 percent the Medicare cost-sharing for specialty tier drugs.", 
  "popular_title": null, 
  "related_bills": [], 
  "short_title": "Medicare Prescription Drug Cost Equalization Act", 
  "sponsor": {
    "district": "8", 
    "name": "Ellsworth, Brad", 
    "state": "IN", 
    "thomas_id": "01851", 
    "title": "Rep", 
    "type": "person"
  }, 
  "status": "REFERRED", 
  "status_at": "2008-07-31", 
  "subjects": [
    "Aging", 
    "Drugs", 
    "Health", 
    "Prescription pricing"
  ], 
  "subjects_top_term": "Health", 
  "summary": {
    "as": "Introduced", 
    "date": "2008-07-31", 
    "text": "Medicare Prescription Drug Cost Equalization Act - Amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act to: (1) require application to specialty tier drugs (very high cost and unique items) of the process for exception from the tiered cost-sharing for drugs included within a formulary; and (2) limit to 25% the Medicare cost-sharing for such specialty tier drugs. (Under an exception, a nonpreferred drug could be covered under the terms applicable for preferred drugs if the prescribing physician determines that the preferred drug for treatment of the same condition either would not be as effective for the individual, or would have adverse effects for the individual, or both. )"
  }, 
  "titles": [
    {
      "as": "introduced", 
      "title": "Medicare Prescription Drug Cost Equalization Act", 
      "type": "short"
    }, 
    {
      "as": "introduced", 
      "title": "To amend part D of title XVIII of the Social Security Act to apply the exceptions process for tiered formulary drugs to specialty tier drugs and to limit to 25 percent the Medicare cost-sharing for specialty tier drugs.", 
      "type": "official"
    }
  ], 
  "updated_at": "2013-02-02T20:48:27-05:00"
}